Hepatitis C: New Treatments in the Pipeline - CD8 T cells - The Body

More documents

Recommendations

Info

A-831 • Albuferon • Bavituximab • B ChronVac-C • Civacir • DEBIO-025 • GS 9450 (LB84451) • GSK625433 • H ITMN-191 (R7227) • Locteron Interfero (Celgosivir) • Nitazoxanide • Omeg PEV2A PEV2B • PF-00868554 • PF-34 Taribavir<strong>in</strong> • Telaprevir (VX-950) • TG40
Page 1 and 2: Hepatitis C: New Treatments in the
Page 3: Table of Contents Foreword . . . .
Page 6 and 7: 4 and from non-strategic prescribin
Page 9 and 10: Introduction Preventing new infecti
Page 11 and 12: Doses of promising candidates have
Page 13 and 14: Table 2 . Re-treatment Trials in No
Page 15 and 16: • HCV researchers have much to ga
Page 17 and 18: Oral Antivirals: HCV Protease and P
Page 19 and 20: naïve people initially, then in th
Page 21 and 22: Table 4. PROVE 2: Interim Results b
Page 23 and 24: Figure 5 . Telaprevir Phase III Tri
Page 25 and 26: Table 5 . Results from a Phase IIa
Page 27 and 28: cyclophilin inhibitors have immunos
Page 29 and 30: An ongoing phase II study is evalua
Page 31 and 32: • Civacir An ongoing, phase II st
Page 33 and 34: Table 9 . Week 12 Results from SELE
Page 35 and 36: • PEV2A PEV2B PEV2A PEV2B uses ma
Page 37 and 38: and ribavirin. Sometimes, HCV re-tr
Page 39 and 40: with hepatitis C. 58th Annual Meeti

Hepatitis C: New Treatments in the Pipeline - CD8 T cells - The Body

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?